Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent Endometrial Cancer: An NRG Oncology/GOG Study

OBJECTIVE: We sought to determine safety and efficacy of the AKT inhibitor, GSK2141795, combined with the MEK inhibitor, trametinib, in endometrial cancer. METHODS: Patients with measurable recurrent endometrial cancer were eligible. One to two prior cytotoxic regimens were allowed; prior use of a M...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Gynecol Oncol
Päätekijät: Westin, Shannon N., Sill, Michael W., Coleman, Robert L., Waggoner, Steven, Moore, Kathleen N., Mathews, Cara A., Martin, Lainie P., Modesitt, Susan C., Lee, Sanghoon, Ju, Zhenlin, Mills, Gordon B., Schilder, Russell J., Fracasso, Paula M., Birrer, Michael J., Aghajanian, Carol
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6922584/
https://ncbi.nlm.nih.gov/pubmed/31623857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2019.09.024
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia